Mi SciELO
Servicios Personalizados
Revista
Articulo
Indicadores
- Citado por SciELO
- Accesos
Links relacionados
- Citado por Google
- Similares en SciELO
- Similares en Google
Compartir
Revista de la OFIL
versión On-line ISSN 1699-714Xversión impresa ISSN 1131-9429
Resumen
SANTOS MORIN, L; LOMBARDERO PIN, M; MATEOS EGIDO, E y VELAZ SUAREZ, MA. Adverse psychiatric effects with lorlatinib, a medicine that has not been widely used. Rev. OFIL·ILAPHAR [online]. 2020, vol.30, n.1, pp.78-79. Epub 18-Ene-2021. ISSN 1699-714X. https://dx.doi.org/10.4321/s1699-714x2020000100021.
Non-small cell lung cancer (NSCLC) is the most common cause of death worldwide. Selective molecular treatments have been an important advance in the treatment of NSCLC in certain patients whose tumors have diverse mutations such as EGFR, BRAF, ALK rearrangement or ROS.
Lorlatinib is an ALK-selective TKI that it is able to penetrate the brain and it has highly activity against ALK and ROS1 fusions, including resistance mutations. We describe the case of a woman with non-small cell lung cancer who has an adverse psychiatric effect in relation to lorlatinib.
Palabras clave : Lorlatinib; ROS1-rearrangement; psychiatric effect.